VolitionRx Limited — FY 2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014; filed March 18, 2015. VolitionRx is a clinical-stage diagnostics company developing blood-based tests using its Nucleosomics platform. Its assays were not approved for clinical diagnostic use; the company began selling research-use-only kits during 2014.
Financial results and liquidity
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue | $14,785 | $0 |
| Operating expenses | $5,952,200 | $4,575,912 |
| Research and development expense | $4,044,023 | $2,503,765 |
| Net operating loss | $5,937,415 | $4,575,912 |
| Net other expense/(income) | $2,276,114 expense | $865,623 income |
| Net loss | $8,213,529 | $3,710,289 |
| Basic and diluted loss per share | $0.61 | $0.34 |
| Cash used in operating activities | $4,140,825 | $3,084,206 |
Revenue was immaterial relative to expenses, so operating margins are not meaningful. The net loss increased 121%, reflecting higher operating costs and a $2.42 million derivative-liability loss, partly offset by $143,987 in grant income. R&D spending rose about 62% year over year.
At year-end, cash was $2,138,964; current assets were $2,335,718 and current liabilities were $2,713,077, a reported working-capital deficit of $377,359. Excluding the $1,577,640 derivative liability, management reported operating working capital surplus of $1,200,281. Total liabilities were $3,064,850, including a $351,773 repayable grant; the filing reports no material off-balance-sheet arrangements. Stockholders’ equity was $368,179.
Financing activities provided $5,737,766 in 2014, principally from share issuance and grants. Subsequent to year-end, the company reported net proceeds of approximately $11.1 million from equity issuances in February and March 2015, plus $55,000 from warrant exercise. These financings followed the February 2015 NYSE MKT uplisting. The filing does not provide a post-financing cash balance or a quantified cash runway.
Material changes and business developments
- R&D expense increased by approximately $1.54 million, with higher clinical-study costs, payroll, share-based compensation, and sample and antibody costs. Patent costs also increased.
- The company reported preliminary results from colorectal cancer studies, including an analysis of 938 symptomatic patients reporting 84% detection of colorectal cancer and 60% detection of precancerous polyps at 78% specificity. These are company-reported study results, not evidence of regulatory approval or established clinical performance.
- The company completed sample collection for a Belgian colorectal study and continued larger retrospective and prospective studies in Denmark. A larger German study was expected to begin testing samples in 2015.
- In 2014, the company launched RUO kits and entered three distribution agreements. RUO kit sales generated the year’s $14,785 revenue.
- In February 2015, the company purchased the patent underlying its NuQ-M tests for $55,000. In February 2015, the ratchet provision on the remaining 409,750 warrants expired and the associated derivative liability was cancelled.
Outlook, risks, and unusual items
Management planned to prioritize clinical Nucleosomics products. It expected to seek European CE marking, initially targeting the NuQ-X assay in 2015, and to explore US market entry through a CLIA laboratory partner for an LDT while pursuing FDA approval. The company estimated CE marking at about $500,000 per NuQ panel and FDA approval at about $5 million per product; these were estimates, not commitments or assured timelines. Point-of-care launches were targeted for Europe in 2017 and the United States in 2018, subject to development and approvals.
The auditor identified substantial doubt about the company’s ability to continue as a going concern, citing accumulated losses of $19.5 million and negative operating cash flows. The company depends on additional financing; it stated that insufficient funding could delay trials and approvals or force it to suspend or discontinue operations. Future equity financing could dilute shareholders. Other key risks include clinical and regulatory uncertainty, evolving FDA oversight of LDTs, competition, and the possibility that assay performance or commercialization may not meet expectations.
A $2.42 million derivative valuation loss materially affected 2014 results. The company also disclosed material weaknesses in internal controls, including inadequate cash controls and incomplete off-site data backup procedures; management concluded disclosure controls and internal control over financial reporting were not effective at year-end. The audited financial statements received an unqualified opinion, but the auditor did not attest to internal-control effectiveness.
Most important facts for investors to verify
- Whether 2015 equity proceeds were received as described, and the resulting cash balance, burn rate, and funding runway.
- Progress, costs, and results of colorectal and other clinical studies, including validation in larger and less-selected patient populations.
- Actual CE-mark and FDA/LDT regulatory pathways, approval requirements, timelines, and costs.
- Whether RUO sales grow beyond the initial $14,785 and whether the company secures commercial partners or meaningful IVD revenue.
- Resolution of the disclosed internal-control weaknesses and the treatment of warrants and derivative liabilities after the ratchet provision expired.